Sept 11 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial ...
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...
GSK Plc’s experimental drug helped prevent serious asthma attacks in two late-stage studies, easing the path forward for a medicine that the British company says could reach £3 billion ($3.9 ...
GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the Big Pharma’s push toward approval despite falling short on some ...
After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...
An analysis of data from the phase 2 portion of the trial showed the primary efficacy objective had not been met. A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine ...
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £18.00. The company’s shares closed yesterday at p1,497. ...
As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares closed yesterday at p1,497. ...
BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK delivered promising response rates in patients with a type of lung cancer, propelling the ...
ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as pharma&'s combo disappoints
In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final analysis of a phase 3 trial. Another study showed that pharma&’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback